tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gibbs JF et al. Outcome analysis of FK 506 therapy for acute and chronic rejection. 1993 Transplant. Proc. pmid:7679823
Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy? Japanese FK 506 Study Group. 1993 Transplant. Proc. pmid:7679824
Alessiani M et al. Adverse effects of FK 506 overdosage after liver transplantation. 1993 Transplant. Proc. pmid:7679825
Klintmalm GB et al. Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679826
Rilo HR et al. Effect of intraportal human islet transplantation on kidney graft survival in simultaneous kidney-islet allografts. 1993 Transplant. Proc. pmid:7680172
Fukuzaki T et al. Induction of unresponsiveness to islet allograft by preoperative donor spleen cell injection and FK 506 treatment. 1993 Transplant. Proc. pmid:7680173
Schweizer M et al. Sensitivity of mitochondrial peptidyl-prolyl cis-trans isomerase, pyridine nucleotide hydrolysis and Ca2+ release to cyclosporine A and related compounds. 1993 Biochem. Pharmacol. pmid:7680201
Hirao A et al. Effects of immunosuppressants, FK506, deoxyspergualin, and cyclosporine A on immature human hematopoiesis. 1993 Blood pmid:7680241
Pancer Z et al. cDNA cloning of a putative protochordate FK506-binding protein. 1993 Biochem. Biophys. Res. Commun. pmid:7505578
Fischer S et al. A mechanism for rotamase catalysis by the FK506 binding protein (FKBP). 1993 Biochemistry pmid:7505615
Thomson AW et al. ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy. 1993 Autoimmunity pmid:7505632
Meiser BM et al. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model. 1993 Transplant. Proc. pmid:7682363
Yu Y et al. Mutagenicity of the new immunosuppressive drugs, FK 506, and spergualin. 1993 Transplant. Proc. pmid:7682364
Rao PN et al. Prediction of early graft function by effluent levels of hyaluronic acid in clinical liver transplantation. 1993 Transplant. Proc. pmid:7682366
McCauley J et al. Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. 1993 Nephrol. Dial. Transplant. pmid:7508098
Nishikawa T et al. Kinetic analysis of molecular interconversion of immunosuppressant FK506 by high-performance liquid chromatography. 1993 Pharm. Res. pmid:7508108
Keicho N et al. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. 1993 J. Antibiot. pmid:7693639
Iwasaki K et al. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. 1993 Res. Commun. Chem. Pathol. Pharmacol. pmid:7508138
Timerman AP et al. The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. 1993 J. Biol. Chem. pmid:7693682
Schwaninger M et al. Inhibition of cAMP-responsive element-mediated gene transcription by cyclosporin A and FK506 after membrane depolarization. 1993 J. Biol. Chem. pmid:7693684
Smith DF et al. FKBP54, a novel FK506-binding protein in avian progesterone receptor complexes and HeLa extracts. 1993 J. Biol. Chem. pmid:7693698
Soldin SJ et al. Immunophilin receptors for immunosuppressive drugs. 1993 Ther Drug Monit pmid:7510077
McMichael J et al. Computer-guided concentration-controlled trials in autoimmune disorders. 1993 Ther Drug Monit pmid:7510078
Ocain TD et al. A nonimmunosuppressive triene-modified rapamycin analog is a potent inhibitor of peptidyl prolyl cis-trans isomerase. 1993 Biochem. Biophys. Res. Commun. pmid:7685167
Asami M et al. Detection of the FK506-FKBP-calcineurin complex by a simple binding assay. 1993 Biochem. Biophys. Res. Commun. pmid:7685169
Fenton M and Kay JE Thapsigargin activates lymphocytes via a different pathway from ionomycin. 1993 Biochem. Soc. Trans. pmid:7510649
Renoir JM et al. Immunological identification of a 50 kDa Mr FK506-binding immunophilin as a component of the non-DNA binding, hsp90 and hsp70 containing, heterooligomeric form of the chick oviduct progesterone receptor. 1993 C. R. Acad. Sci. III, Sci. Vie pmid:7522118
Jung-Testas I et al. [Inhibition of the anti-glucocorticosteroid effect of RU486 on the growth of mouse fibroblasts in culture by the immunosuppressor kf506]]. 1993 C. R. Acad. Sci. III, Sci. Vie pmid:7522119
Roelen DL et al. Differential inhibition of primed alloreactive CTLs in vitro by clinically used concentrations of cyclosporine and FK506. 1993 Transplantation pmid:7687397
Antoni FA et al. Inhibitory role for calcineurin in stimulus-secretion coupling revealed by FK506 and cyclosporin A in pituitary corticotrope tumor cells. 1993 Biochem. Biophys. Res. Commun. pmid:7687429
Denesyuk AI et al. Comparison of conformations of cyclosporin A and macrolide FK506 fragments: localization of putative binding sites with phosphatase calcineurin. 1993 Biochem. Biophys. Res. Commun. pmid:7687433
Viebahn R et al. Simulation of hypoxic and preservation injury in human hepatocyte cultures: influence of FK 506 and cyclosporine. 1993 Transplant. Proc. pmid:7689278
Dé P et al. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3? 1993 Transplant. Proc. pmid:7689279
Ueda D et al. Influence of FK 506 on renal blood flow. 1993 Transplant. Proc. pmid:7689280
Ohzato H et al. Serum interleukin-6 levels as an indicator of acute rejection after liver transplantation in cynomologous monkeys. 1993 Surg. Today pmid:7689373
Galvin F et al. Effects of cyclosporin A, FK 506, and mycalamide A on the activation of murine CD4+ T cells by the murine B7 antigen. 1993 Eur. J. Immunol. pmid:7678228
Foxwell BM et al. Inhibition of activation-induced changes in the structure of the T cell interleukin-7 receptor by cyclosporin A and FK506. 1993 Eur. J. Immunol. pmid:7678231
Hirai T et al. Prolonged lung allograft survival with a short course of FK 506. 1993 J. Thorac. Cardiovasc. Surg. pmid:7678313
Sattler M et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. 1992 Sep-Oct Drug Metab. Dispos. pmid:1385058
Bowman H and Lennard TW Immunosuppressive drugs. 1992 Nov 4-17 Br J Hosp Med pmid:1282440
Nazer H et al. FK 506 associated disorders in liver transplantation. 1992 May-Jun J. Gastroenterol. Hepatol. pmid:1377038
Arai S et al. The impact of FK506 on graft coronary disease of rat cardiac allograft--a comparison with cyclosporine. 1992 Jul-Aug J. Heart Lung Transplant. pmid:1379829
Fagiuoli S et al. FK 506: a new immunosuppressive agent for organ transplantation. Pharmacology, mechanism of action and clinical applications. 1992 Jul-Aug Ital J Gastroenterol pmid:1381245
Tong J et al. Effect of FK-506 and cyclosporin A on in vitro CFU-GM growth in severe aplastic anemia patients. 1992 Jul-Aug Haematologica pmid:1385279
Mizuno K et al. Modulation of multidrug resistance by immunosuppressive agents: cyclosporin analogues, FK506 and mizoribine. 1992 Jan-Feb Anticancer Res. pmid:1373592
Bishop DK and Li W Cyclosporin A and FK506 mediate differential effects on T cell activation in vivo. 1992 J. Immunol. pmid:1371128
Yasunami Y et al. Induction of donor-specific unresponsiveness in rat islet allografts by FK 506. 1992 Transplant. Proc. pmid:1376510
Barry JM Immunosuppressive drugs in renal transplantation. A review of the regimens. 1992 Drugs pmid:1281071
Takai K et al. Effects of FK506 on rat thymic epithelial cells; immunohistochemical study. 1992 Thymus pmid:1378235
Nielsen JB et al. Yeast FKBP-13 is a membrane-associated FK506-binding protein encoded by the nonessential gene FKB2. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1380159